Introduction
============

Cellular microparticles (MPs) are fragments of the plasma membrane that are shed by virtually all cell when subject to a number of stress conditions, including cellular activation and apoptosis ([@b6-vhrm-4-0769]; [@b54-vhrm-4-0769]; [@b20-vhrm-4-0769]; [@b26-vhrm-4-0769]). Since the description of "platelet dust" by [@b51-vhrm-4-0769], numerous studies have reported the presence of subcellular vesicles in centrifuged plasma. Although long considered to be cellular debris, blood MPs are more recently considered reflective of cellular stimulation, activation, and degeneration/apoptosis ([@b19-vhrm-4-0769]; [@b38-vhrm-4-0769]; [@b10-vhrm-4-0769]). By general consensus, MPs are small in size (≤1.5 μm), expose the anionic phospholipid (PL) phosphatidylserine (PS) on the outer leaflet of their membrane, and bear surface membrane antigens reflecting their cell of origin ([@b30-vhrm-4-0769]). MPs that arise from the cellular components of blood and the endothelial lining of blood vessels are referred to as blood MPs. Apart from blood MPs, plasma contains smaller membrane vesicles (40--100 nm) termed exosomes and larger vesicles (\>1.5 μm) termed apoptotic bodies that are derived from blood and vascular cells ([@b23-vhrm-4-0769]; [@b19-vhrm-4-0769]). The aim of this article is to review the technical aspects of characterizing the morphological and functional properties of blood MPs with emphasis on both preanalytical and analytical variables.

Membrane phospholipid asymmetry and microparticle formation
===========================================================

All cell type's spontaneously shed blebs from their plasma membranes in an active process that appears to be important for membrane remodeling and antigenic turnover. In resting cells, the negatively charged phospholipids, including PS, are almost exclusively present in the inner leaflet of the cell membrane ([@b54-vhrm-4-0769]). Among the mechanisms proposed to account for this asymmetry are unidirectional enzymatic movement by an aminophospholipid translocase and/or association between the negatively charged phospholipids and elements in the cytoplasm, including cytoskeletal elements and their accompanying proteins ([@b8-vhrm-4-0769]). MP release is an integral part of the cell membrane remodeling process whereby the normal asymmetric distribution of phospholipids between the two leaflets of the plasma membrane is lost. Calcium entry, activation of calpain and scramblase activity are thought to be important steps in the loss of lipid asymmetry and microparticle formation, but the exact sequence of events is not completely understood ([@b18-vhrm-4-0769]; [@b53-vhrm-4-0769]; [@b16-vhrm-4-0769], [@b15-vhrm-4-0769]; [@b40-vhrm-4-0769], [@b41-vhrm-4-0769]; [@b11-vhrm-4-0769], 2006; [@b31-vhrm-4-0769]). The possible pathways leading to membrane budding and MP release have been recently reviewed ([@b19-vhrm-4-0769]; [@b10-vhrm-4-0769]).

Membrane shedding by blood cells
================================

Erythrocytes
------------

Shedding processes are found in a variety of blood cells ([@b6-vhrm-4-0769]). Human erythrocytes treated with ionophore A23187 in the presence of calcium, respond by budding to release MPs. Normal erythrocytes also release MPs following ATP depletion, heat treatment (49 °C), incubation at pH 5.4 and incubation with diamide (5 mMol/L) ([@b47-vhrm-4-0769]). Erythrocyte MPs are also found to be elevated in several pathological conditions associated with hemolysis ([@b27-vhrm-4-0769]) but are notably elevated in sickle cell anemia ([@b1-vhrm-4-0769]). Erythrocyte-derived MPs are usually identified by the binding of antibodies to glycophorin A (CD235a), a protein uniquely expressed on the erythrocyte membrane.

White blood cells
-----------------

These cells have a unique physiological role in inflammation, immune regulation, and thrombosis. Following exposure to various stimuli including lipopolysaccharide and phorbol myrisitate, monocytes are observed to vesiculate and release MPs ([@b44-vhrm-4-0769]; [@b36-vhrm-4-0769]). Monocytes express CD14, the lipopolysaccharide receptor strongly on their surface while granulocytes express CD14 weakly. Thus, monocyte-derived MPs have been identified by the surface expression of CD14. MPs derived from neutrophils have been identified in the blood of normal subjects and in patients with meningoccocal sepsis ([@b39-vhrm-4-0769]). Typically, polymorphonuclear neutrophilic leukocyte-derived MPs are identified using the leukocyte-specific markers lactoferrin or CD66b. Lymphocyte-derived MP have been identified using lymphocyte-specific markers CD4 and CD8 ([@b3-vhrm-4-0769]; [@b4-vhrm-4-0769]; [@b17-vhrm-4-0769]; [@b35-vhrm-4-0769]).

Platelets
---------

Microparticle formation in platelets occurs as a result of activation by various stimuli (epinephrine, adenosine diphosphate, collagen, thrombin, A23187) ([@b24-vhrm-4-0769]) and during storage ([@b9-vhrm-4-0769]). Increased platelet MP formation has been documented in a variety of clinical conditions that are associated with platelet activation ([@b46-vhrm-4-0769]). Platelet-derived MPs that express surface glycoproteins and antibodies to CD41, CD42, and CD61 have been used to detect platelet-derived MPs ([@b32-vhrm-4-0769]; [@b13-vhrm-4-0769]; [@b17-vhrm-4-0769]). CD61 is less specific as a platelet marker since this integrin is also expressed on blood monocytes and antibodies that recognize on the CD61 epitope will identify both platelet and monocyte-derived MPs.

Endothelial cells
-----------------

Endothelial cells undergo injury and vesiculation following *in vitro* exposure to complement, thrombin and a variety of agents such as ionophore, lipopolysaccharide, autoantibodies, and cytokines (interleukin-1 and tumor necrosis factor-α) ([@b21-vhrm-4-0769]; [@b14-vhrm-4-0769]). Elevated endothelial MPs have been documented in several pathological situations including atherosclerosis, sepsis, and diabetes mellitus. Several endothelial specific antibodies have been used to detect MPs in these situations including CD31, CD51, CD105, CD144, and CD146 ([@b43-vhrm-4-0769]). Of this extensive list, CD144 and CD146 are endothelial-specific markers as they have not yet been found expressed on any other blood cell in humans.

Assays to characterize microparticles
=====================================

In general, most assays have focused on characterizing the antigenic composition of cellular microparticles using antibody capture-based ELISA ([@b4-vhrm-4-0769]; [@b20-vhrm-4-0769]; [@b34-vhrm-4-0769]) or flow cytometry ([@b13-vhrm-4-0769], [@b14-vhrm-4-0769]). Most investigators have elected to characterize blood MPs using flow cytometry and the technical protocols of some have been reviewed in a recent forum ([@b30-vhrm-4-0769]). In addition to analyzing MP antigens, several investigators have assessed the coagulant function of blood microparticles using functional assays ([@b49-vhrm-4-0769]; [@b34-vhrm-4-0769]; [@b7-vhrm-4-0769]; [@b29-vhrm-4-0769]; [@b45-vhrm-4-0769]; [@b2-vhrm-4-0769]). These assays either measure acceleration of plasmatic coagulation by MP-derived phospholipids or triggering of plasmatic coagulation by MP-associated tissue factor. The PF3 assay, in which exposure of platelet poor plasma to Russell's viper venom in the presence of calcium causes coagulation, but only in the presence of certain phospholipids (supplied by blood MPs), has also been used as a functional assay ([@b22-vhrm-4-0769]).

Preanalytical variables
-----------------------

The measurement of blood MPs requires careful attention to collection and processing of blood samples. While there have been some general guidelines regarding preanalytical variables that may be important, these have been more consensus-driven statements rather than guidelines based on scientific evidence. Furthermore, several aspects of blood collection such as venepuncture needle size, use of a tourniquet during blood collection, phlebotomy using a vacutainer vs a syringe, and the type of anticoagulant used (sodium citrate vs ethylenediaminetetraacetic acid) could have an impact on the measurement of blood MPs. Additionally, sample processing following blood collection is extremely variable between investigators and could be partially responsible for the discrepancies in blood MPs levels reported in the literature. While separating the cellular elements of blood from the plasma containing MPs, careful attention must be paid to centrifugation speed. In our experience, a 2-step centrifugation using 1500 × g for 10 minutes and then 13,000 × g for 10 minutes resulted in platelet-free plasma (when assessed by flow cytometry and light microscopy) ([@b45-vhrm-4-0769]). The second centrifugation step is particularly efficient at rendering plasma relatively "platelet free" by eliminating small platelets but it is unclear if large bloods MPs are also depleted in this process. There are several difficulties in separating platelets, microparticles, exosomes, and cellular debris as individual components. We have attempted to isolate blood MPs from platelet-poor plasma by using a high-speed centrifugation step. However, the sample that we work with contains exosomes. Isolating blood MPs from exosomes by centrifugation is technically challenging and the need for such separation is probably dependent on the nature of the study being performed.

Analytical variables
--------------------

### Flow cytometry

Flow cytometric analysis of blood MPs appears to be the most favored method to characterize blood MPs ([@b30-vhrm-4-0769]). Typically, MPs are identified as particles with a forward angle light scatter (FALS) smaller than an internal standard consisting of 1--1.5 μm sized latex particles ([@b45-vhrm-4-0769]). Most investigators do not use a lower size limit but some have arbitrarily chosen 100 nm below which particles that are recognized by the instrument are not considered MPs ([@b10-vhrm-4-0769]). Others have used platelets as an internal standard and gated particles with a FALS value below that of the smallest platelet ([@b39-vhrm-4-0769]). While the identification of MPs on the basis of size using FALS tests the limit of sensitivity of flow cytometry, some have overcome this problem by adjusting the parameters of the instrument to detect fluorescent intensity ([@b25-vhrm-4-0769]). Flow cytometry can also be used to enumerate blood MPs by adding a known number of fluorescent or nonfluorescent latex particles to the sample prior to performing analysis ([@b13-vhrm-4-0769], [@b14-vhrm-4-0769]; [@b45-vhrm-4-0769]). The number of MPs present in the sample is derived by dividing the number of MP events counted by the volume of the sample analyzed, ie, (beads counted/beads added) × sample volume, and adjusting for the final dilution of the original blood sample. Alternatively, if the flow cytometry instrument delivers the sample to the optics cell by screw-driven syringe at a known rate, then the sample MP count can theoretically be calculated. This method of enumeration is less desirable since it makes assumptions regarding the instruments fluidics and has unacceptable day-to-day variability ([@b42-vhrm-4-0769]).

### Antibody capture assays

ELISA-based MP capture assays have been devised and tested to simplify and semi-automate the characterization of blood MPs. These assays have utilized annexin V as a means of capturing phospholipids ([@b4-vhrm-4-0769]; [@b34-vhrm-4-0769]) or antibodies to specific blood MP membrane antigens, eg, αIIbβ3 ([@b33-vhrm-4-0769]), or antibodies to nonspecific blood MP membrane antigens that are shared by several cell types eg, antibody 1B5 ([@b2-vhrm-4-0769]) and have been reviewed elsewhere ([@b20-vhrm-4-0769]). Such assays have reduced the challenges of analyzing large sample numbers.

### Other assays

In addition to the above techniques, the antigenic characteristics and the membrane composition of blood MPs have been studied using electron microscopy ([@b23-vhrm-4-0769]; [@b2-vhrm-4-0769]) ([Figure 1](#f1-vhrm-4-0769){ref-type="fig"} and [Figure 2](#f2-vhrm-4-0769){ref-type="fig"}), confocal microscopy ([@b14-vhrm-4-0769]), high performance liquid chromatography ([@b48-vhrm-4-0769]), capillary electrophoresis ([@b52-vhrm-4-0769]), and mass spectrometry ([@b28-vhrm-4-0769]; [@b37-vhrm-4-0769]) with varying degrees of success. Assays that measure the pro/anticoagulant functions of blood MPs are somewhat under-utilized perhaps in part due to the technical challenges in developing standardized and reproducible assays.

Limitations
-----------

Flow cytometry provides useful information about blood MPs but there are some limitations associated with this technique that are worth considering. The definition of a blood MP using flow cytometry is still an area of great debate. In our studies, we used somewhat rigid criteria to define blood MPs in order to preserve specificity while sacrificing sensitivity to a certain extent. Blood MPs were defined as particles that were 1. Removable from platelet-free plasma by ultracentrifugation; 2. Were small in size (≤1 μm); and 3. Labeled with annexin V. While such criteria may be possible in certain situations, they are not practical or possible in all conditions. For instance, most would agree that blood MPs demonstrate surface PS as evidenced by annexin V labeling, but clearly not all plasma particles ≤1 μm label with annexin V ([@b45-vhrm-4-0769]; [@b10-vhrm-4-0769]). Furthermore, a substantial portion of plasma particles ≤1 μm label with antibodies to cell surface markers, but not annexin V, which suggests that there are PS (--) blood MPs ([@b45-vhrm-4-0769]). An alternative explanation could be that the exposure of PS on the outer aspect of some blood MPs is incomplete resulting in absent/reduced annexin V labeling or that some MPs contain scramblase activity. Finally, the contribution of exosomes and apoptotic bodies to the flow cytometric signal obtained cannot be completely ignored. Thus, while a consensus flow cytometric definition of blood MPs would have utility, one should be aware of the limitations of such definitions when studying biological processes. Modern flow cytometers are equipped with less powerful lasers and have a threshold for particle size detection ∼500 nm below which sensitivity is unpredictable according to instrument manufacturers (Becton Dickenson, San Jose, CA; pers comm). Detecting MPs using fluorescence as the primary detection parameter has overcome this problem to a certain extent, but most investigators do not clearly indicate instrument setting in their description of the methods. Finally, the choice of well-characterized antibodies directed against a cell membrane antigen that not shared by other cell lineages present in blood is an important prerequisite to characterizing the cellular origin of blood MPs. Such antibodies should be primarily labeled with a flsourophore, as the use of secondary antibodies is not recommended.

Microparticles in health and disease
====================================

The general consensus is that plasma levels of blood MPs reflect equilibrium between their release and their clearance by monocytes-macrophage system. Since clearance of cells undergoing apoptosis or injury is extremely efficient, the presence of blood MPs is considered an objective *in vitro* parameter that serves as evidence of deleterious cellular alterations *in vivo*. However, very little is published about the clearance and fate of blood MPs in any specific disease state leaving one to speculate that their presence reflects either a defect in recognition of these particles or an overwhelming of the clearance mechanism by their sheer number ([@b50-vhrm-4-0769]). Experimental evidence both *in vitro* and *in vivo* has demonstrated that blood MPs are capable of influencing diverse biological function ([@b54-vhrm-4-0769]; [@b5-vhrm-4-0769]; [@b24-vhrm-4-0769]; [@b36-vhrm-4-0769]; [@b19-vhrm-4-0769]; [@b26-vhrm-4-0769]; [@b10-vhrm-4-0769]). Blood MPs have been associated with several disease processes and while they seem to be useful markers there is insuffiscient evidence to demonstrate that this association is causal. Clearly, elevated blood MPs in several disease processes result from inflammation, cellular activation and apoptosis. Such MPs, through their diverse biological effects, unequivocally contribute to vascular disease and comorbidity and are therefore likely to be very important in the disease process.

Conclusion
==========

Several studies clearly demonstrate that blood MPs could be mediators of disease in some cases, markers of disease in other cases, and have prognostic potential, but the patho-physiological relevance of blood MPs is still in its infancy. Many of the studies mentioned in this review demonstrate that detection, phenotypic characterization, and quantification of blood MPs are interesting and potentially valuable in patients that are at risk for vascular events. However, conversion of this potential into a reality will necessitate a standardized approach to the detection and characterization of blood MP. In addition, attention to the preanalytical and analytical variables and refinement in the techniques used to assess the cellular origin of blood MPs could help shed light on the mechanisms of MP release, function, and clearance.
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![Ultrastructure of blood MPs from a patient with sickle cell anemia using electron microscopy.](vhrm-4-0769f1){#f1-vhrm-4-0769}

![Immunogold labeling of blood MPs. Blood MPs obtained by ultracentrifugation were incubated with rabbit polyclonal anti-tissue factor antibody (**a**; 6 nm gold), anti-CD144 antibody (**b**; 12 nm gold), and anti-CD14 antibody (**c**; 12 nm gold). No labeling was observed with control antibodies (**d**, **e**, and **f**).\
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